Corporate Governance6 Nov 2026, 08:11 pm
Molbio Diagnostics: IPO Proceeds Utilization Report for Q3 2026
AI Summary
Molbio Diagnostics Ltd has submitted its Monitoring Agency Report for the quarter ended September 30, 2026, detailing the utilization of proceeds from its Initial Public Offering (IPO). The report, issued by CRISIL Ratings Limited, confirms that there have been no deviations from the stated objects for the utilization of the IPO funds. The company raised ₹2,000.00 million (₹200 Crore) through its IPO, with net proceeds of ₹1,872.81 million (₹187.28 Crore) after accounting for issue expenses. This report has been reviewed and taken on record by the Audit Committee and Board of Directors.
Key Highlights
- Monitoring Agency Report on IPO proceeds utilization submitted.
- CRISIL Ratings confirms no deviation from IPO fund utilization objects.
- IPO raised ₹2,000 million (₹200 Crore) with net proceeds of ₹1,872.81 million.
- Report covers the quarter ended September 30, 2026.
- Reviewed by Audit Committee and Board of Directors.
Price Impact
More from MOLBIO